Researchers say aspirin use may be linked to Brilinta's effectiveness

From ACC:

Bloomberg News (10/30, Kelley) reports that "AstraZeneca Plc is looking into whether greater use of aspirin reduces the effectiveness of its experimental clot-busting medicine Brilinta [ticagrelor]." Earlier this year, the drug "beat Sanofi-Aventis SA and Bristol- Myers Squibb Co.'s blood thinner Plavix [clopidogrel] in a study, preventing 16 percent more heart attacks, strokes, and deaths." On Thursday, however, the drugmaker "said...that researchers noticed a link between higher doses of aspirin and Brilinta's potency." Reuters (10/29) also covered the story
Sent from my Verizon Wireless BlackBerry